Skip to main content

P21 vs PE-22-28

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

P21

P21 is a synthetic peptide derived from Cerebrolysin, specifically designed to mimic the neurotrophic effects of the parent compound. It promotes neurogenesis and has shown cognitive-enhancing properties in research.

Full details →

PE-22-28

PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.

Full details →

Side-by-Side Comparison

AspectP21PE-22-28
Dose Range1 mg–5 mg500 mcg–2 mg
Frequency1x daily1x daily
Cycle Length2–4 weeks1–2 weeks
Routesubcutaneoussubcutaneous
MechanismInhibits glycogen synthase kinase-3β (GSK-3β) and activates CREB signaling pathway. This promotes BDNF expression, neurogenesis in the hippocampus, and synaptic plasticity.Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways.
Typical DosageResearch protocols typically use 1-5mg administered intranasally or subcutaneously. Often used in cycles of 2-4 weeks.Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established.
AdministrationCan be administered intranasally for direct CNS access or subcutaneously. Best used cyclically rather than continuously.Intranasal administration preferred for CNS delivery. Research compound with limited human use data.
Side EffectsLimited data. Reported effects include mild headache, temporary brain fog during initial use, and fatigue.Very limited human data. Primarily studied in animal models for safety and efficacy.
Best For

What They Have in Common

P21, PE-22-28 are both commonly used for:

Key Differences

Unique to PE-22-28:

Which Has Stronger Evidence?

  • Cognitive Performance: P21 has stronger research support.
GoalP21PE-22-28
Cognitive Performancemediumlow

Ready to Learn More?